SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Cancer Discovery
Antoni RibasRobert S Janssen

Abstract

PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection-site reactions and transient, mild-to-moderate "flu-like" symptoms. Among the 9 patients naïve to anti-PD-1 therapy, the overall response rate (ORR) was 78%. The estimated 12-month progression-free survival rate was 88%, and the overall survival rate was 89%. Among 13 patients having prior anti-PD-1 therapy, the ORR was 15%. RNA profiling of tumor biopsies demonstrated increased CD8+ T cells, natural killer cells, cytotoxic cells, dendritic cells, and B cells. The combination of intratumoral SD-101 and pembrolizumab was well tolerated and induced broad immune activation in the tumor microenvironment with durable tumor responses in both peripheral and visceral lesions.Significance: These early data demonstrate that the combination of pembrolizumab with intratumoral SD-101 is well tolerated and can induce immune activation at the tumor site. Combining ...Continue Reading

References

Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Apr 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ManegoldN Thatcher
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vera HirshJoan H Schiller
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 20, 2016·JAMA : the Journal of the American Medical Association·Antoni RibasCaroline Robert
Nov 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Shu WangCristiana Guiducci
Mar 23, 2017·Expert Opinion on Biological Therapy·Pol Specenier
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Jan 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ManegoldN Thatcher

❮ Previous
Next ❯

Citations

Apr 3, 2019·Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale·M C MerlanoO Garrone
Oct 4, 2019·Nature·Olivier DemariaEric Vivier
Aug 31, 2019·Nature Reviews. Immunology·Stefanie K WculekDavid Sancho
Feb 7, 2020·Pigment Cell & Melanoma Research·Abdullah Al EmranPeter Hersey
Nov 30, 2019·Biological Chemistry·Sandra Santos-Sierra
Dec 1, 2019·The Oncologist·Omid HamidIgor Puzanov
Apr 17, 2020·Clinical and Experimental Immunology·M SegoviaM Hill
Jun 9, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Nana DangYuan Lin
Sep 8, 2019·Nature Reviews. Cancer·Michael S Goldberg
Sep 27, 2019·Nature Reviews. Drug Discovery·Claire Vanpouille-BoxLorenzo Galluzzi
Jul 12, 2020·The British Journal of Dermatology·X Bai, K T Flaherty
Oct 2, 2019·Nature Reviews. Immunology·Anusha Kalbasi, Antoni Ribas
Apr 20, 2019·Frontiers in Immunology·Nathan SuekDanny N Khalil
Jul 23, 2019·The Journal of Clinical Investigation·Danny N KhalilTaha Merghoub
Jun 13, 2020·Frontiers in Pharmacology·Jian-Ye ZhangLi-Wu Fu
Jan 7, 2020·Cancer Immunology, Immunotherapy : CII·Akshay J PatelGary W Middleton
Jun 20, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory V GoldmacherLawrence H Schwartz
Apr 26, 2019·Anti-cancer Drugs·Marcella OccelliMarco C Merlano
Apr 5, 2020·Journal of Hematology & Oncology·Chongxian PanLei Zheng
May 24, 2020·Annals of the New York Academy of Sciences·Martha Lopez-YrigoyenJeffrey W Pollard
May 20, 2020·Frontiers in Immunology·Michael H ZhangGregory L Szeto
Jun 26, 2020·International Journal of Molecular Sciences·Pierpaolo GinefraNicola Vannini
Aug 14, 2019·Frontiers in Immunology·Nadine S JahchanMatthew F Krummel
Jun 18, 2020·Frontiers in Immunology·Yu-Chen ChuangTsung-Hsien Chuang
Mar 7, 2020·Frontiers in Immunology·Mohanraj ManangeeswaranDaniela Verthelyi
Mar 21, 2020·Frontiers in Aging Neuroscience·Pramod N NeheteHenrieta Scholtzova
Mar 22, 2020·Current Oncology Reports·Nalan Akgul Babacan, Zeynep Eroglu
Jan 10, 2019·Journal for Immunotherapy of Cancer·Kerstin KappManuel Schmidt
Mar 8, 2020·Cells·Charles Robert LichtensternMichael Karin
Apr 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Tanya E Keenan, Sara M Tolaney
May 30, 2020·Cancer Discovery·Davis Y TorrejonAntoni Ribas
Jan 25, 2020·Cancer Discovery·Annabelle J AnandappaPatrick A Ott
Sep 29, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ivan Marquez-RodasIgnacio Melero
May 28, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark AleynickJoshua D Brody
Jan 16, 2020·Immunity·Jackson G EgenLawren C Wu
Jan 23, 2021·Cancer Cell·Egle RamelyteReinhard Dummer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.